结核病与肺部健康杂志 ›› 2020, Vol. 9 ›› Issue (1): 37-43.doi: 10.3969/j.issn.2095-3755.2020.01.009

• 论著 • 上一篇    下一篇

顺铂联合雷帕霉素或3-甲基腺嘌呤对肺腺癌A549细胞抑制作用的研究

卜静, 杜芸(), 纪晓坤, 吴家宁   

  1. 050000 石家庄,河北医科大学第四医院细胞学室
  • 收稿日期:2020-01-09 出版日期:2020-03-30 发布日期:2020-04-17
  • 通信作者: 杜芸 E-mail:bujing_edu@sina.com
  • 基金资助:
    河北省卫生厅重点科技研究计划(20130644)

Inhibitory effect of cisplatin combined with rapamycin or 3-methyladenine in lung adenocarcinoma A549 cells

BU Jing, DU Yun(), JI Xiao-kun, WU Jia-ning   

  1. Department of Cytology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
  • Received:2020-01-09 Online:2020-03-30 Published:2020-04-17
  • Contact: DU Yun E-mail:bujing_edu@sina.com

摘要:

目的 观察非小细胞肺癌(non small cell lung cancer, NSCLC)中肺腺癌A549细胞在顺铂(cisplatin, CP)联合雷帕霉素(rapamycin, RAPA)或3-甲基腺嘌呤(3-methyladenine, 3-MA)作用下的结果,为提高顺铂的化疗效果提供理论依据。方法 2013年3月至2014年6月期间,通过对人肺腺癌细胞株A549(由河北医科大学第四医院科研中心提供)经四甲基偶氮唑盐3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium (MTT)实验检测顺铂、雷帕霉素和3-MA对A549细胞的增殖抑制率,计算出各药物的50%细胞抑制浓度(50% inhibitory concentration,IC50),并以此作为实验浓度。实验分为4组:对照组(无药物干预)、顺铂组(加15μmol/L的顺铂)、顺铂+雷帕霉素组(加10 nmol/L的雷帕霉素 1h后再加15μmol/L的顺铂)、顺铂+3-MA组(加3μmol/L的3-MA 1h后再加15μmol/L的顺铂),将对数生长期的肺癌A549细胞以每孔1.0×106/ml密度接种于6孔培养板中,待细胞长至孔底面积约70%~80%后分别加入稀释好的药物,分别培养24、48、72h。肺癌A549细胞的生长迁移情况用细胞划痕实验检测,mTOR、LC3-Ⅱ及Bax mRNA和蛋白的表达情况用RT-PCR(逆转录-聚合酶链反应)、 Western blot(蛋白质印迹)法检测。数据处理采用SPSS 17.0统计软件进行分析。结果 顺铂 IC50:15μmol/L;雷帕霉素 IC50:10 nmol/L;3-MA IC50:3μmol/L。划痕实验显示24h 顺铂+雷帕霉素组细胞迁移能力最弱,48h和72h 顺铂+3-MA组细胞迁移能力最弱。RT-PCR显示顺铂+雷帕霉素组LC3-ⅡmRNA的2-△△Ct值(24h:1.686±0.069;48h:1.803±0.083;72h:1.836±0.056)与顺铂组(24h:1.489±0.031;48h:1.325±0.007;72h:1.428±0.080)相比表达量均明显上升(24h F=149.780,P<0.01;48h F=111.599,P<0.01;72h F=167.855,P<0.01);而顺铂+3-MA组的Bax mRNA的2-△△Ct值(48h:1.864±0.104;72h:1.935±0.068),与顺铂组(48h:1.346±0.080,72h:1.462±0.029)相比,表达量均明显上升(48h F=52.853,72h F=202.118;P值均<0.01)。Western blot显示顺铂+雷帕霉素组LC3-Ⅱ蛋白(48h:0.556±0.010;72h:0.571±0.009)与顺铂组(48h:0.426±0.0107;72h:0.492±0.009)相比表达量均显著上升(48h F=372.056,72h F=930.500;P值均<0.01);而顺铂+3-MA组的Bax 蛋白(48h:0.897±0.022;72h:0.916±0.005),与顺铂组(48h:0.463±0.011;72h:0.581±0.007)相比,表达量均显著上升(48h F=1100.412,72h F=5715.778;P值均<0.01)。结论 顺铂联合雷帕霉素或3-MA较单独使用顺铂能更好的抑制A549细胞的生长,长时间用药时顺铂联合3-MA作用最强。

关键词: 肺肿瘤, 顺铂, 西罗莫司, 肿瘤细胞,培养的, 抑制,化学性, 药物筛选试验,抗肿瘤

Abstract:

Objective To observe the inhibition effect of cisplatin (CP) combined with rapamycin (RAPA) or 3-methyladenine (3-MA) on lung adenocarcinoma A549 cells, so as to provide evidence for improving the chemotherapeutic effectiveness of CP. Methods From March 2013 to June 2014, we accessed human lung adenocarcinoma A549 cells from the scientific research center of the Fourth Hospital of Hebei Medical University. Cells’ proliferation inhibition rate and the 50% inhibitory concentration (IC50) of CP, RAPA and 3-MA were obtained by conducting tetramethylazozolium 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium (MTT) experiment and those IC50s were used in the inhibitory experiment. Four groups were studied: control group (without drug intervention), CP group (15 μmol/L of CP), CP+RAPA group (10nmol/L of RAPA followed by 15 μmol/L of CP), CP+3-MA group (add 3 μmol/L of 3-MA for 1 hour and then add 15 μmol/L of CP). The A549 cells in logarithmic growth phase were seeded into 6-well plates with a concentration of 1.0×106/ml. When the cells grew to cover about 70%-80% of the bottom area of the well, diluted drugs were added and cells then were cultured for 24 h, 48 h, 72 h. The growth and migration of A549 cells were detected by cell scratch test, and the expression of mTOR, LC3-Ⅱ and Bax mRNA and proteins were detected by RT-PCR and Western blot test. Data were processed and analyzed using SPSS17.0 statistical software. Results The IC50 results of MTT experiment were 15 μmol/L for CP, 10 nmol/L for RAPA, and 3 μmol/L for 3-MA. Scratch experiments showed that the weakest migration ability was in CP+RAPA group at 24 h and CP+3-MA group at 48 h and 72 h. RT-PCR showed that the expressions of LC3-Ⅱ mRNA in CP+RAPA group (2-△△Ct: 24 h 1.866±0.069, 48 h 1.803±0.083, 72 h 1.836±0.056) were significantly increased (24 h F=149.780, 48 h F=111.599, 72 h F=167.855, P<0.01) compared with CP group (2-△△Ct: 24 h 1.489±0.031, 48 h 1.325±0.007,72 h 1.428±0.080), while the expressions of Bax mRNA in CP+3-MA group (2-△△Ct: 48 h 1.864±0.104, 72 h 1.935±0.068) were increased significantly (48 h F=52.853, 72 h F=202.118, P<0.01) compared with CP group (2-△△Ct: 48 h 1.346±0.080, 72 h 1.462±0.029). Western blot test showed that the expressions of LC3-Ⅱ protein in CP+RAPA group (2-△△Ct: 48 h 0.556±0.010, 72 h 0.571±0.009) were significantly higher than that of CP group (2-△△Ct: 48 h 0.426±0.0107, 72 h 0.492±0.009) (48 h F=372.056, 72 h F=930.500, P<0.01), and the expressions of Bax protein in CP+3-MA group (2-△△Ct: 48 h 0.897±0.022, 72 h 0.916±0.005) were significantly higher than that of CP group (2-△△Ct: 48 h 0.463±0.011, 72 h 0.581±0.007), (48 h F=1100.412, 72 h F=5715.778, P<0.01). Conclusion CP combined with RAPA or 3-MA can inhibit the growth of A549 cells better than CP alone. CP combined with 3-MA has the strongest effect when used for a long time.

Key words: Lung neoplasms, Cisplatin, Sirolimus, Tumor cells, cultured, Depression, chemical, Drug screening assays, antitumor